Melodiol Global Health (ASX:ME1) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

ME1 Stoklara Genel Bakış

Melodiol Global Health Limited, Avrupa, Kanada, Avustralya ve Asya Pasifik'te eğlence amaçlı ve tıbbi kenevir ürünlerinin geliştirilmesi, yetiştirilmesi ve dağıtımı ile ilgilenmektedir.

Şirket hakkında

ME1 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 17.7% oranında azaldı

Negatif hissedar öz sermayesi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Anlamlı bir piyasa değeri yok ( A$1M )

+ 1 daha fazla risk

Melodiol Global Health Limited Rakipler

Wellfully

ASX:WFL

AU$1.5m

Invex Therapeutics

ASX:IXC

AU$6.2m

Firebrick Pharma

ASX:FRE

AU$11.7m

Cann Global

ASX:CGB

AU$5.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Melodiol Global Health
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.001
52 Haftanın En Yüksek Seviyesi	AU$4.20
52 Haftanın En Düşük Seviyesi	AU$0.001
Beta	2.5
11 Aylık Değişim	0%
3 Aylık Değişim	-50.00%
1 Yıllık Değişim	-99.97%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	-100.00%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 01

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Mar 02

Recent updates

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

May 01

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

Mar 02

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

May 11

Hissedar Getirileri

	ME1	AU Pharmaceuticals	AU Pazar
7D	0%	1.4%	0.1%
1Y	-100.0%	91.9%	18.3%

Getiri vs. Endüstri: ME1 geçen yıl % 98.5 oranında getiri sağlayan Australian Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: ME1 geçen yıl % 17.9 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ME1's price volatile compared to industry and market?
ME1 volatility
ME1 Average Weekly Movement	44.9%
Pharmaceuticals Industry Average Movement	10.3%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.5%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: ME1 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ME1 'nin haftalık oynaklığı son bir yılda 63% dan 44% a düştü, ancak hâlâ Australian hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	n/a	Will Lay	melodiolglobalhealth.com

Melodiol Global Health Limited, Avrupa, Kanada, Avustralya ve Asya Pasifik'te eğlence amaçlı ve tıbbi kenevir ürünlerinin geliştirilmesi, yetiştirilmesi ve dağıtımı ile ilgilenmektedir. Nutrasötik ürünlerin geliştirilmesi ve ticarileştirilmesi ve tıbbi malzeme işiyle ilgilenmektedir. Şirket daha önce Creso Pharma Limited olarak biliniyordu ve Haziran 2023'te adını Melodiol Global Health Limited olarak değiştirdi.

Melodiol Global Health Limited Temel Bilgiler Özeti

Melodiol Global Health'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ME1 temel i̇stati̇sti̇kler
Piyasa değeri	AU$1.13m
Kazançlar(TTM)	-AU$35.52m
Gelir(TTM)	AU$18.92m

0.1x

P/S Oranı

0.0x

F/K Oranı

ME1 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ME1 gelir tablosu (TTM)
Gelir	AU$18.92m
Gelir Maliyeti	AU$18.10m
Brüt Kâr	AU$817.00k
Diğer Giderler	AU$36.34m
Kazançlar	-AU$35.52m

Son Raporlanan Kazançlar

Dec 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.032
Brüt Marj	4.32%
Net Kâr Marjı	-187.73%
Borç/Özkaynak Oranı	-232.0%

ME1 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ME1 Stoklara Genel Bakış

Ödüller

Risk Analizi

Melodiol Global Health Limited Rakipler

ASX:WFL

AU$1.5m

ASX:IXC

AU$6.2m

ASX:FRE

AU$11.7m

ASX:CGB

AU$5.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

New major risk - Negative shareholders equity

Recent updates

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 3 million.

Melodiol Global Health Limited (ASX:ME1) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Melodiol Global Health Limited, Annual General Meeting, May 31, 2024

Investors Give Melodiol Global Health Limited (ASX:ME1) Shares A 59% Hiding

New major risk - Negative shareholders equity

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.

Melodiol Global Health Limited Option Expiring 13 November 2028 Deferred Settlement Deleted from OTC Equity

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215 million.

Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.231808 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 1.022261 million.

Melodiol Global Health Limited has filed a Follow-on Equity Offering in the amount of AUD 1.010906 million.

First half 2023 earnings released: AU$0.013 loss per share (vs AU$0.006 loss in 1H 2022)

Melodiol Global Health Limited has completed a Follow-on Equity Offering in the amount of AUD 0.574725 million.

Panacea Life Sciences Holdings, Inc. (OTCPK:PLSH) entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million.

Here's Why Creso Pharma (ASX:CPH) Can Afford Some Debt

Full year 2022 earnings released: AU$0.022 loss per share (vs AU$0.027 loss in FY 2021)

Creso Pharma Limited (ASX:CPH) entered into a binding letter of intent to acquire Abby & Finn, LLC for $2.5 million.

Creso Pharma Limited Announces Board Changes

Less than half of directors are independent

Creso Pharma Limited Announces Director Appointments

Creso Pharma Limited Announces Board Changes

First half 2022 earnings released: AU$0.006 loss per share (vs AU$0.018 loss in 1H 2021)

Sierra Sage Secures USD 214,000 Purchase Order from Walmart

Creso Pharma Limited (ASX:CPH) signed a non-binding, non-exclusive heads of agreement to acquire Dr Pickles Pty Ltd.

Less than half of directors are independent

Creso Pharma Limited, Annual General Meeting, May 31, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Creso Pharma Limited announced that it expects to receive AUD 5 million in funding

Creso Pharma to Develop New Hemp-Based Lozenge Product

Creso Pharma Limited Launches New E-Commerce Channels

First half 2021 earnings released: AU$0.018 loss per share (vs AU$0.08 loss in 1H 2020)

Creso Pharma Limited (ASX:CPH) completed the acquisition of Halucenex Life Sciences Inc.

Co-Founder & Non-Executive Chairman recently sold AU$4.5m worth of stock

Creso Pharma Limited Launches New Product

Creso Pharma Limited (ASX:CPH) entered into an agreement to acquire Halucenex Life Sciences Inc. CAD 10 million.

Creso Pharma Limited Signs Non-Binding Letter of Intent with ImpACTIVE Holdings Ltd

Full year 2020 earnings released: AU$0.083 loss per share (vs AU$0.10 loss in FY 2019)

Creso Pharma Limited Executes A Non-Binding Letter of Intent with Ceres Natural Remedies

Creso Pharma Limited Revises Earnings Guidance for the Fiscal Year 2021

Creso Pharma Limited Announces Distribution Agreement with Route2 Pharm Pvt Ltd

CBD Oil legal in Australia - Creso Pharma Limited to benefit

Creso Pharma Limited has announced a Derivatives Offering in the amount of AUD 9.523042 million.

Creso Pharma Limited Secures New Purchase Order for its Leading Range of Animal Health Products Anibidiol

Creso Pharma Limited Secures First Purchase Order for Animal Health Products in LATAM

Creso Pharma Limited Announces TGA Decision to Reschedule CBD

New 90-day high: AU$0.23

Creso Pharma Limited Receives New Purchase Orders for Anibidiol® Products

Creso Pharma Limited Receives Second Purchase Order from Pharma Dynamics, South Africa

Creso Pharma Limited announced that it expects to receive AUD 8.992531 million in funding

First half earnings released

Creso Pharma Limited Announces CEO, Miri Halperin Wernli to Take Role of Technology, Innovation and Distribution Head

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Melodiol Global Health Limited Temel Bilgiler Özeti

0.1x